A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was in osteogenesis imperfecta (OI) patients with valve disease undergoing valve replacement which type of valve (bioprosthetic or mechanical) is most appropriate in terms of safety, complications and survival. Altogether more than 77 papers were found as a result of the reported search, of which 43 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Previous review articles have presented case reports up to 2009. As all published data are based on case reports, we conducted a more detailed analysis that included the aforementioned series, reports that were missed prior to 2009 and all published data from 2009 to October 2013. Our analysis identified 43 OI patients. Mechanical valves were used in the majority of cases (31 patients), bioprosthetic valves in 10 patients and homografts in 2 patients. We conclude that based on the best available evidence, it appears that bioprosthetic valves have had better outcomes (mortality rate 10%) and a lower valve-related complication rate (0%) compared with mechanical valves (mortality rate 16.1%, complication rate 16.1%), even though differences were not statistically significant. Although the existing evidence is solely based on case reports of a relatively small number, we would suggest the use of bioprosthetic valves in OI patients with valve disease, as they appear to be safer according to our analysis. Moreover, considering the surgical difficulties related to the friability and weakness of the tissues in terms of suture lines and implantation of the valve as well as the high risk of perioperative bleeding which can be related to tissue friability, capillary fragility and platelet dysfunction followed by the risk of major traumatic fractures and a possible risk of aortic dissection in the future, the bioprosthetic valves seem to be safer taking into account the avoidance of lifelong anticoagulation and its secondary bleeding complications.
INTRODUCTION
Patients with osteogenesis imperfecta (OI), an autosomal dominant disorder of connective tissue that can cause significant pathology in the cardiovascular system, have a compromised life span due to complications related to connective tissue friability. A best evidence topic was constructed according to a structured protocol to assess which type of prosthetic valve should be recommended for this group of patients. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
A 40-year old male patient with OI has been referred to the department of cardiac surgery with aortic valve regurgitation. The consultant cardiac surgeon is asking you which type of valve would be most appropriate and safest for valve replacement in this patient. 
SEARCH STRATEGY
SEARCH OUTCOME
Seventy-seven papers were found as a result of the reported search. From these, 54 were identified to be related to our research. Further assessment of these revealed that only 43 were suitable for our criteria (Table 1) and 12 were excluded due to isolated valve repairs (and not replacements) or language other than English [2, 4, [16] [17] [18] [19] [20] .
RESULTS
Two review articles were identified in the literature that gathered data from all existing published case reports. As all published data are based on case reports, we conducted a more detailed analysis including the two aforementioned series plus reports that were missed prior to 2009, as well as all published data from 2009 to October 2013 consistent with our three-part question (Table 1) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] .
Our analysis identified 43 OI patients (39 males, mean age 39.2 years, age range 18-63 years) who underwent valve surgery. A total of 55 valves were operated upon, of which 51 were replaced (4 concomitant repairs). Of the valves replaced, 37 were aortic and 14 mitral, with combined valve operations having been performed in 12 patients (27.9% of patients) of which 8 were double (aorticmitral) replacements (same type of valve), 3 aortic valve repair/ mitral valve repair and 1 mitral valve repair/aortic valve repair.
Mechanical valves were used in the majority of cases (31 patients), bioprosthetic valves in 10 patients and homografts in 2 patients.
A total of 17 patients (39.5% of patients) experienced complications, 15 of whom received mechanical valves and 2 bioprosthetic valves. Twenty-one complication incidences were reported in total, of which 19 occurred in patients who received a mechanical valve and 2 in patients who received bioprosthetic valves. Of these, valve-related complications were observed in 5 patients and included 1 re-replacement (Mech), 1 dehiscence (Mech), 1 left ventricular rupture (Mech), 1 paravalvular leak (Mech) and 1 massive myocardial infarction (Mech). General complications that may be attributed to either the operation or the disease itself included bleeding (n = 10; 2 Bio/8 Mech), 1 left ventricular systolic dysfunction (Mech), 1 postoperative pneumonia (Mech), 1 stroke (Mech), 1 heart failure (Mech) and 2 aortic dissections (15 and 18 years postop). Notably, the incidence of aortic dissection in this sample of patients is interestingly high (4.7%) compared with that of the normal population.
According to the type of valve used, mechanical valves yielded a 16.1% (5 of 31 patients) valve-related complication rate compared with 0% of bioprosthetic valves (P = 0.2; Fisher's exact test).
Bleeding, which is a common complication in OI patients, is difficult to be solely attributed to the type of the valve inserted. There seem to have occurred no significant difference between mechanical and bioprosthetic valve implantation, as it was observed in 20% of patients treated with bioprosthetic valves (2 of 10 patients) and in 25.8% of patients who had a mechanical valve (8 of 31 patients).
Total mortality was 9 patients (21.4%; 8 males), 8 of whom were treated with a mechanical valve. Three of the patients died of causes unrelated to the valve replacement: 1 because of accidental detachment from ventilator, 1 from heart failure 21 months postoperatively and 1 from aortic dissection 18 years postoperatively. Operative mortality for patients who received mechanical valves was 16.1% (5 of 31 patients) compared with 10% (1 of 10 patients) for bioprosthetic valves (P = 0.5; Fisher's exact test). The only patient who died after a bioprosthetic valve insertion was the first patient who received this type of valve, in 1968. The two homografts that were used led to no complications and good outcomes.
Postoperative follow-up was reported in 14 patients and ranged from 4 to 216 months (median: 12 months, interquartile range: 5.75-27 months).
CLINICAL BOTTOM LINE
Based on the best available evidence, it appears that bioprosthetic valves have had better outcomes (mortality rate 10%) and a lower valve-related complication rate (0%) compared with mechanical valves (mortality rate 16.1%, complication rate 16.1%), even though differences were not statistically significant. Although the existing evidence is solely based on case reports of a relatively small number, we would suggest the use of bioprosthetic valves in OI patients with valve disease, as they appear to be safer according to our analysis.
Regarding the definitive decision of the type of valve that should be used, we have to carefully consider the surgical difficulties related to friability and weakness of the tissues due to the underlying connective tissue disorder in terms of suture lines and implantation of the valve (dehiscence of the valve or paravalvular leak). Additionally, these patients have a high risk of perioperative bleeding complications despite the normal preoperative coagulation status which can be related to tissue friability, capillary fragility and platelet dysfunction [2, 21] . Thereafter, these patients remain at risk of major traumatic fractures and a possible higher incidence of aortic dissection.
Therefore, bearing in mind the above findings and the potentially increased risk of bleeding complications secondary to lifelong anticoagulation, bioprosthetic valves seem to be a safer choice.
